Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
